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Abstract: Herpes simplex virus is responsible for numerous ocular diseases, the most common 
of which is herpetic stromal keratitis. This is a recurrent infection of the cornea that typically 
begins with a subclinical infection of the cornea that establishes a latent infection of sensory gan-
glia, most often the trigeminal ganglia. Recurring infections occur when the virus is reactivated 
from latency and travels back to the cornea, where it restimulates an inflammatory response. This 
inflammatory response can lead to decreased corneal sensation, scarring, and blindness. The 
diagnosis of these lesions as the result of a recurrent herpes simplex virus infection can at times 
be problematic. Currently, herpetic stromal keratitis is diagnosed by its clinical presentation 
on the slit-lamp examination, but the literature does not always support the accuracy of these 
clinical findings. Other diagnostic tests such as polymerase chain reaction assay, enzyme-linked 
immunosorbent assay, immunofluorescent antibody, and viral cultures have provided more 
definitive diagnosis, but also have some limitations. That said, accurate diagnosis is necessary 
for proper treatment, in order to prevent serious consequences. Current treatment reduces the 
severity of lesions and controls further viral spread, but does not provide a cure.
Keywords: herpes simplex virus, herpetic stromal keratitis, cornea
Introduction
Herpes simplex virus (HSV) is a ubiquitous DNA virus that can infect virtually 
anywhere in the body, particularly when newborns are infected.1–3 However, in an 
individual with a normal immune system, the most common sites of infection are the 
mouth, genitalia, and eyes. In very young children, and in rare instances adults, the 
brain may also become infected. HSV infections of the eye are the leading cause of 
infectious corneal blindness in developed countries.4 Approximately 500,000 people 
in the US are currently infected with ocular HSV.5,6 The costs of treatment for this 
disease are in the tens of millions spent annually in the US alone.6 While most infec-
tions are unilateral, around 1.3%–12% of affected individuals have bilateral ocular 
infections. Bilateral infections are seen mostly in immunocompromised patients.7–9 
Infections can occur in both anterior and posterior segments of the eye, but it most 
commonly infects the corneal epithelia.4,7,8 It is primarily diagnosed by its clinical 
presentation, but atypical presentation of the infection can impede accurate diagnoses 
and thus proper treatment.10
Pathophysiology
HSV is a linear double-stranded DNA virus that is classified as an α-member of the 
Herpesviridae family.5,11 Primary infection results after HSV spread via direct con-
tact with mucous membrane of the host.5,11 In the case of ocular infections, the virus 
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is transported following primary retrograde infection via 
sensory neurons to establish latency in trigeminal ganglia; 
here, it remains asymptomatic until reactivation of the virus 
leads to secondary or recurrent infections.4,8,12,13 The host 
cell’s DNA polymerase, located in the nucleus of the cell, 
is required for HSV to transcribe and replicate.8,14
Herpetic stromal keratitis (HSK) comprises three major 
subtypes: epithelial, stromal, and endothelial (Figure 1).15 
Clinical findings in epithelial keratitis include geographic 
corneal ulcers with a dendritic tail or dendritic keratitis. 
This occurs after direct invasion by the virus and is the most 
common subtype.13,15 SK develops as a result of immune 
Figure 1 Representative images of various corneal damages due to HSv1 infection.
Notes: (A) Large herpetic epithelial dendrite at graft–host junction. (B) Large subepithelial bulla due to HSv endotheliitis. (C) Ring-lipid deposit surrounding a focal HSv 
disciform keratitis. (D) Large geographic herpetic ulcer in Hiv patient. (E) Herpetic keratouveitis with anterior chamber inflammation (layered hypopyon due to WBC 
accumulation), small keratic precipitates (wBC aggregates on the corneal endothelial surface), and corneal edema (due to endothelial dysfunction). (F) Large herpetic 
epithelial dendrite. (G) Postherpetic neurotrophic epithelial defect due to corneal nerve damage by HSv1. (H) Large herpetic corneal scar with iris incarceration to the side 
of corneal perforation.
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Challenges in herpes simplex keratitis
response to the virus. The stromal subtype can be further 
divided into disciform keratitis, immune SK, and necrotizing 
keratitis. Endothelial keratitis manifests as rejection line-like 
keratic precipitates and stromal edema. Variation in presen-
tation between different subtypes has posed a challenge in 
accurately diagnosing this condition.15
Diagnosis
HSK is primarily diagnosed by its clinical presentation on 
the slit-lamp examination.4 Common symptoms include 
redness, discharge, watery eyes, irritation, itching, pain, 
and photophobia. In most patients, symptoms begin to 
subside after the first 2 weeks.4 The most common subtype, 
epithelial keratitis, appears as coarse granular spots that 
form punctuate lesions, but these quickly coalesce to form 
dendritic lesions.16–18 A physical examination may reveal 
whitened area.19 On the slit-lamp examination, epithelial 
keratitis presents as a dendritic lesion with a terminal bulb, 
swollen borders, and intraepithelial cell infiltration.15 It 
is visualized by staining the lesion with either lissamine 
green or rose bengal dye.20 For atypical epithelial lesions, 
polymerase chain reaction (PCR) has been used to con-
firm HSK.21 Newer methods, such as tear collection and 
immunofluorescence antibody assay (IFA), have also been 
employed to aid identification of epithelial lesions.22,23 SK 
on physical examination appears opaque or whitened, due to 
stromal infiltration.20,24 Similarly, the necrotizing form of SK 
appears as gray-white or opaque, but there is accompanying 
necrosis and ulceration on slit-lamp examination.20,24 Edema 
and abscess may be apparent as well.4,25 In immunomediated 
SK, necrosis or ulceration is lacking, but there is stromal 
infiltration.26 Unfortunately, PCR has been less helpful for 
identification of immunomediated SK. Another form of 
HSK, disciform lesion, has a ground-glass appearance and is 
disk shaped with stromal edema on slit-lamp  examination.27 
Lastly, the endothelial form, keratic precipitates, and iritis 
may be visible. Stromal edema is also present.27 Enzyme-
linked immunosorbent assay (ELISA) and viral cultures have 
been used as diagnostic tools for all subgroups of lesions.15,28 
Dendritiform epithelial lesions on slit-lamp examination 
are pathognomonic for keratitis. However, atypical lesions 
can make diagnosis difficult.15 Factors affecting diagnosis 
include duration of illness, systemic diseases, previous medi-
cation use, and corneal transplantation, as these can change 
the appearances of lesions on slit-lamp examination.21
Misdiagnosis in clinical settings is not uncommon, as 
other pathogens can present with similar lesions.10 Amebic 
and fungal infections have been mistakenly identified as 
HSV keratitis.13 In a study conducted by Rübben et al, 8% 
of the clinically diagnosed HSV lesions were identified 
on PCR assay as lesions caused by another member of the 
Herpesviridae family – varicella zoster virus.29 Similarly, 
another study uncovered 5% of clinically diagnosed HSK 
lesions as lesions caused by adenovirus, 3.2% as lesions 
caused by cytomegalovirus, and 2.7% by enterovirus.30 
When PCR was used to confirm clinical diagnosis of 
epithelial dendritiform lesions, there was only moderate 
correlation (K=0.485, P,0.0001) between diagnosis made 
by an ophthalmologist and diagnosis made using PCR.10 In 
a study designed to address the diagnosis of atypical HSK 
lesions, Koizumi et al defined atypical lesions as those where 
“dendritic or geographical ulcers with terminal bulbs and 
epithelial infiltrations are not evident”. They found very 
little agreement (P=0.22) between PCR results and clinical 
diagnosis.21
While most diagnoses of HSK are based on clinical 
presentation, PCR provides better sensitivity. In a study con-
ducted by El-Aal et al, PCR detected 29.2% more cases than 
cell culture.22 In another study, while viral culture identified 
12% of suspected patients with HSK, PCR identified 88% 
of suspected patients.22 PCR is highly sensitive, but large 
variation has been observed in various studies between the 
rate of HSV detection by PCR when compared to clinical 
diagnosis.10 PCR is more likely to identify patients that 
present with typical lesions or patients who have not used 
antiviral medications (P=0.022). It is less responsive in 
patients with atypical lesions or in patients who previously 
used or currently use antiviral medications (P=0.968).28 It 
has been hypothesized by McGilligan et al that because 
SK is a result of immune response to the virus, rather than 
the viral infection itself, it may explain the negative PCR 
results. Variation was also seen (4%–6% variability) when 
the same samples were reanalyzed using different amplifi-
cation regions of the gene.10 In another study, there was an 
80% decrease of detectable virus in patients who had been 
taking 400 mg of acyclovir twice daily.31 This can lead to 
reduction in PCR sensitivity.13 PCR-based tests can also 
result in false negatives.31,32
Similarly, ophthalmologists use oxybuprocaine, a local 
anesthetic that is used in conjunction with fluorescein-based 
dye to visualize possible HSV corneal lesions better, but can 
decrease the effectiveness of PCR by interfering with the 
PCR reaction, resulting in a decrease of more than 2 logs 
(DNA copies/sample).33 Other dyes, such as rose bengal and 
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PCR assays require corneal scrapings. Unfortunately, 
patients with recurrent infections may have decreased cor-
neal thickness, thus restricting the ophthalmologist from 
performing corneal scraping to obtain a specimen.23 Alter-
natively, viral load can be determined from patient tears.23 
Satpathy et al compared viruses collected by this less inva-
sive technique with that collected by corneal scraping using 
immunofluorescence assay, PCR, and viral titering.23 The 
results indicated that immunofluorescence assay detected 
viral antigen in 12.53% of tear specimens and 22.87% of 
corneal scrapings, PCR detected the virus in 13.97% of tear 
specimens and 36.66% of corneal scrapings. Lastly, infec-
tious virus was detected from 5.2% of tears and 11.11% of 
corneal scrapings. While PCR of virus collected from tears 
was more sensitive than both viral isolation and immunofluo-
rescence from tears, it was significantly less sensitive than 
corneal scrapings (P,0.0005).23 Once again, the timing of 
testing tear film is a concern, as the virus rarely persists as 
long as the corneal lesions do.23
Along with PCR, ELISA has also been used to detect virus 
in tear collections. Shoji et al measured HSV DNA using 
real-time PCR and measured HSV-specific secretory immuno-
globulin A (IgA) antibody using ELISA in tears of clinically 
suspected HSK patients.15 Overall, sensitivity of ELISA was 
49.2% and specificity 82.6%. On the other hand, sensitivity and 
specificity for real-time PCR were higher at 55.8% and 100%, 
respectively, in tears collected. However, when divided into 
subgroups, real-time PCR detected HSV DNA levels in the 
disciform keratitis subgroup (median 3.1×102 copies/sample), 
significantly less than it detected HSV DNA in the den-
dritic/geographic keratitis subgroup (median 2.3×104 copies/
sample) (P,0.05, Mann–Whitney test). Detection of HSV 
DNA was also low in the atypical subgroup.15 Furthermore, 
viral load in tears decreased after day 11 of illness which could 
have further increased false negatives in all subgroups.15
Viral culture is considered the gold standard for identifying 
HSV.28 When compared to viral culture, clinical diagnosis 
is only 55%–65% accurate.28 Unfortunately, culturing HSV 
is time-consuming and can take a week or longer when few 
infectious viruses are in the sample, and typically underesti-
mates the number of patients whose disease is due to HSV.23,35 
IFA has also been used to diagnose HSV and detects 33.3% 
more positive cases than viral culture. It also had sensitivity of 
80%, specificity of 71.4%, positive predictive value of 63.6%, 
and negative predictive value of 81.8%. In other studies, the 
sensitivity of IFA in diagnosing HSV ranged from 77% to 
86%.22 However, sample size and false-positive and false-
negative results can unfavorably influence IFA.23
HSK is a leading cause of corneal blindness.4 Accurate 
and prompt diagnosis is necessary to start the proper treat-
ment and prevent further complications. Variation in differ-
ent subtypes has posed a challenge to accurately diagnose 
HSK.15 This has also prevented a unified or specific test from 
properly diagnosing all of the different subtypes in a quick 
and effective manner.
Challenges to clinical management
Most infections of HSK are self-limiting, even without 
treatment. However, healing is prolonged without the use of 
proper medication, and inappropriate treatment can worsen 
corneal inflammation and lead to recurring lesions and vision 
loss. On the other hand, other subtypes, such as geographic 
epithelial keratitis, are difficult to treat and require prolonged 
therapy.13 Although episodes can be self-limiting, it is essen-
tial to treat the infection at the earliest onset to reduce viral 
replication, shorten disease course, and maintain latency, in 
order to prevent further complications.
Current treatment for HSK includes acyclovir, ganci-
clovir, triflurothymidine, penciclovir, and valacyclovir.13,36 
Acyclovir and its derivatives are nucleoside analogs that are 
selectively phosphorylated by the virally encoded thymidine 
kinase to be used as a substrate by DNA polymerase; this 
drug is not a substrate for the host thymidine kinase, and 
thus has a reduced side-effect profile. Once the analog is 
phosphorylated, it is incorporated into the viral DNA as it 
is being synthesized. Since this analog does not possess the 
chemical structure for subsequent nucleosides to be added, 
this results in chain termination and prevents viral replication 
by inhibiting DNA elongation.8,37,38 Because it affects only 
newly synthesized viral DNA, it does not cure infected cells 
of the virus, but it does prevent new viruses from being pro-
duced. Since acyclovir has poor bioavailability, high doses 
and increased frequency of administration are required.8,36,39,40 
Valacyclovir, another nucleoside analog, has improved 
bioavailability, and thus it has reduced frequency of admin-
istration and can lead to better patient adherence.41 Both 
acyclovir and valacyclovir can cause nausea, vomiting, 
diarrhea, and other gastrointestinal side effects.41 Ganciclovir 
works in a similar manner as acyclovir. Though it has fewer 
side effects, it can cause blurred vision, punctuate keratitis, 
and eye irritation.8,42,43 Nonetheless, long-term treatment 
with these nucleoside analogs has resulted in resistance, 
especially in immunocompromised hosts, due to mutations 
in thymidine kinase or in DNA polymerase, which are 
selected for when the immune system does not efficiently 
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Challenges in herpes simplex keratitis
treatment includes foscarnet and cidofovir, but they have 
less specificity for viral DNA and are more likely to have 
significant toxicity in patients. Early generation drugs, such 
as idoxuridine, iododeoxyuridine, vidarabine, and trifluridine, 
are no longer used, because of increased side-effect profile 
and low bioavailability.8,47
As alluded to earlier, current treatment for HSV does not 
provide a cure, but rather decreases duration of symptoms and 
helps maintain the virus in latency. Recurrence can still occur, 
despite treatment with antiviral drugs. In the HEDS study, 
oral administration of 400 mg of acyclovir decreased ocular 
HSV1 diseases by 45% (32% placebo vs 19% acyclovir).48 In 
another study, recurrence of ocular HSV diseases was 23.1% 
in patients taking acyclovir.49 Risk of recurrence is 20% by 
2 years, 40% by 5 years, and 67% by 7 years, and the risk 
increases with subsequent episodes. It should be stressed 
that acyclovir does not prevent SK, as the pathogenesis of 
SK is immunomediated, though by reducing viral load it 
can reduce the magnitude of the inflammatory response. 
Topical steroids help reduce progression of stromal inflam-
mation, but they do not decrease epithelial disease.7 A quick 
summary of current treatment for different subtypes can be 
found in Table 1.
Relapsing and recurring stromal and endothelial diseases 
significantly increase the risk of corneal scarring from fibrosis 
and neovascularisation.4,7,8,11 Reactivation can be attributed 
to stress, trauma, and ultraviolet radiation.51,52 Endothelial 
keratitis due to recurrent infections can cause cell loss, per-
manent swelling, corneal scarring, opacities, tissue damage, 
and irregular astigmatism.53,54 As the number of episodes 
increases, corneal sensitivity to mechanical stimulation 
decreases.53
Stromal infections are immunomediated and are the 
leading cause of corneal blindness in developed countries. 
They occur as a result of chronic viral reactivation, and 
lead to neurotrophic keratitis, a degenerative condition. 
A normal cornea is densely innervated, but lacks blood ves-
sels. Subsequent episodes not only damage nerves, leading to 
decreased corneal sensation (corneal hypoesthesia), but also 
lead to angiogenesis, and neovascularization.53,54 Decreased 
corneal sensation leads to loss of the corneal blink reflex.54 
This immunomediated reaction occurs as a result of cytok-
ines released by CD4+ T cells.55–57 While recurrent episodes 
of HSK can lead to stromal opacification, long-term use of 
antiviral drugs to prevent future episodes can increase the 
risk of resistance and toxicity.5,6,11 Since stromal response is 
immunomediated, steroids can help decrease recurrence, but 
they do not eliminate the virus.8,58
Additional changes due to HSK include changes in corneal 
thickness. In a study conducted by Wilhelmus et al, corneal 
thickness of disciform SK decreased 15% (95% confidence 
interval 10%–20%).59 Other complications include necro-
tizing SK, where ulceration and necrosis of the cornea are 
visible on slit-lamp examination.56,60 Keratitis has also been 
shown to cause dryness in patients with stromal infection.53
Each subsequent episode increases the patient’s risk of 
developing corneal scaring and blindness. As current treat-
ment helps maintain latency and only shortens the course of 
the disease, all infected patients are at risk of reactivation. 
Corneal scarring that leads to blindness is an indication 
for corneal transplantation. However, transplantation is 
complicated by increased risk of graft rejection in patients 
with HSK.10
Conclusion
HSK is an infection of the cornea caused by HSV. Primary 
infection is the result of direct exposure of the host’s mucous 
membranes to infectious HSV. Following primary infection 
and the establishment of latency in the sensory ganglia, the 
virus can be stimulated to enter an infectious cycle, from 
which it returns to the cornea. Once there, this recurrent 
infection can cause various complications, in particular an 
inflammatory response, which if strong enough can compro-
mise the integrity of the cornea, leading to corneal scarring 
and in severe cases blindness.
HSK is primarily a clinical diagnosis based on the find-
ings of the split-lamp examination. Dendritiform epithelial 
lesions on slit-lamp examination are pathognomonic for 
keratitis. However, previous studies have shown that ocular 
lesions caused by cytomegalovirus, herpes zoster, adenovi-
rus, and fungal infections have been misdiagnosed as HSK 
lesions.7,10,11 Other diagnostic tests, such as PCR assay, 
ELISA, IFA, and viral cultures, have provided a more defini-
tive diagnosis, but have their own limitations. Additionally, 
variation in different subtypes of keratitis has made diagnosis 
of atypical lesions more difficult.
Accurate and prompt diagnosis is necessary to aid 
the physician to know which treatment will have the best 
Table 1 Summary of current treatment for different subtypes
Subgroup Treatment
epithelial subtype Antiviral agents13
Stromal subtype Combination of topical corticosteroids 
and antiviral agents27
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outcomes and thus prevent further complications. Latency 
of HSV has prevented pharmacotherapy from eliminating 
the virus. Current pharmacotherapy treatments have helped 
decrease recurrence and maintain latency, but secondary 
infections can still occur.23,24 Recurring lesions increase 
a patient’s risk of developing fibrosis, scarring, and neo-
vascularization of the cornea. SK, an immunomodulated 
response, is the major cause of decreased corneal sensation 
and blindness. Acyclovir is not effective against the inflam-
matory stage of SK, as there is little virus to be found during 
peak inflammation. It should be noted that each episode of 
recurrent infection increases the risk of subsequent episodes 
and further complicates clinical management.4
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